Skip to main content
Sekar Kathiresan, MD, Cardiology, Boston, MA

SekarKathiresanMD

Cardiology Boston, MA

Adult Congenital Heart Disease

Associate Professor, Medicine-Massachusetts General Hospital, Harvard Medical School

Dr. Kathiresan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kathiresan's full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Cardiovascular Disease, 2000 - 2002
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1997 - 2000
  • Harvard Medical School
    Harvard Medical SchoolClass of 1997

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1999 - 2024

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2011

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Recall by Genotype and Cascade Screening for Familial Hypercholesterolemia in a Population-Based Biobank from Estonia  
    Sekar Kathiresan, Pradeep Natarajan, Nature
  • DNA Sequence Variation in ACVR1C Encoding the Activin-Receptor like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes  
    Derek Klarin, Pradeep Natarajan, Ruth McPherson, Sekar Kathiresan, Krishna Aragam, Alexander Bick, Diabetes Care
  • Genome-Wide Polygenic Scores for Common Diseases Identify Individuals with Risk Equivalent to Monogenic Mutations  
    Amit V Khera, Steven A Lubitz, Sekar Kathiresan, Patrick T Ellinor, Krishna G Aragam, Pradeep Natarajan, Nature

Press Mentions

  • 12 Diseases and Health Conditions Local Biotech Companies Are Tackling Right Now
    12 Diseases and Health Conditions Local Biotech Companies Are Tackling Right NowFebruary 21st, 2023
  • Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
    Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial ResultsNovember 7th, 2022
  • Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?
    Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?August 15th, 2022
  • Join now to see all